GlassScriptPhysician profile
Heather Davis-Lopez
NPI 1588160295
$4,656.92
in general payments reported to CMS, 2019-2025
26 companies · $834 in 2025
The $834 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,685 · 2022: $859 · 2023: $691 · 2024: $587 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,109.29 | 2021-2025 | Airsupra |
| Medtronic, INC. | $542.52 | 2021-2023 | Interstim |
| Abbott Laboratories | $264.14 | 2021-2025 | Freestyle Libre |
| Dexcom, INC. | $261.78 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Inspire Medical Systems, INC. | $252.14 | 2023-2025 | Inspire |
| Esperion Therapeutics, INC. | $233.87 | 2021 | |
| Horizon Therapeutics Plc | $230.83 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $200.72 | 2022 | |
| Novo Nordisk INC | $174.64 | 2023-2025 | Wegovy |
| Biomarin Pharmaceutical INC. | $133.93 | 2025 | Voxzogo 1.2mg |
| Kyowa Kirin, INC. | $125.00 | 2025 | |
| Lilly USA, LLC | $124.99 | 2023 | Mounjaro |
| Intuity Medical INC | $124.71 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Amgen INC. | $118.51 | 2021 | |
| Averitas Pharma INC. | $117.09 | 2024 | Qutenza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $111.58 | 2024 | Gvoke Hypopen |
| Insulet Corporation | $104.03 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $88.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $68.57 | 2022-2023 | Seglentis |
| Genentech USA, INC. | $67.89 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $62.42 | 2021 | |
| Nevro Corp. | $40.08 | 2024 | Senza |
| Globus Medical, INC. | $37.96 | 2025 | Senza |
| Corcept Therapeutics | $28.49 | 2024 | Korlym |
| Pfizer INC. | $17.73 | 2023 | |
| Mannkind Corporation | $15.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Davis-Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.